- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01595269
The Clinical and Economic Impacts of e-Heath on Diabetes (eHealthDM)
8. maj 2012 opdateret af: Dr. Danièle Pacaud
This project addresses the following Null Hypotheses:
- There will be no difference will be found in the use of the search engine and the information accessed among the three education modes.
- There will be no difference in education mode's effect on metabolic control, self-care management practices, and medical resource utilization.
- There will be no difference in the economic impact on the health care system based on differing education modes.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In addition to the face-to-face education process currently used at the CHR, this project will develop two modes of eHealth education.
Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals.
These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information.
This allows for the tracking of the type and amounts of diabetes information accessed by participants.
Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information.
Education mode 2 will be assessed and approved by CHR.
Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts).
In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team.
Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board).
New sites and articles will be added on an ongoing basis.
Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
79
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Alberta
-
Lethbridge, Alberta, Canada
- Calgary Health Region's offices across southwestern Alberta
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Aged 18 or older
- Literate
- Not participating in other clinical trials
- Diabetes diagnosed within the last three months
- Type 2 diabetes
- No medical conditions that could compromise metabolic control
- No linguistic, cognitive or psychosocial barriers that would hinder study completion
- Computer and internet literate
- Access to high-speed internet
Exclusion Criteria:
- Under the age of 18
- Not literate
- Participating in other clinical trials
- Diabetes diagnosed greater than three months ago
- Type 1 diabetes
- Gestational diabetes
- Additional medical conditions that could compromise metabolic control
- Linguistic, cognitive or psychosocial barriers that would hinder study completion
- Not computer and internet literate
- No access to high-speed internet
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Education mode 1 (control)
Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals.
These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information.
This allows for the tracking of the type and amounts of diabetes information accessed by participants.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
|
Aktiv komparator: Education mode 2 (static interface)
Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information.
Education mode 2 will be assessed and approved by CHR.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
|
Aktiv komparator: Education mode 3 (dynamic interface)
Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts).
In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team.
Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board).
New sites and articles will be added on an ongoing basis.
Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
|
In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in A1C
Tidsramme: baseline, 3, 6, 9, 12 months
|
A1C is a measure of metabolic control in diabetes.
For this study changes in A1C from baseline to 3, 6, 9 and 12 months were measured.
All A1C were measured in provincial laboratories using 6.1% as the upper limit of normal for individuals without diabetes.
|
baseline, 3, 6, 9, 12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
a reduction in the cost of delivering health information and education processes
Tidsramme: baseline and 12 months
|
Secondary effects could include a change in the cost of delivering health information and education processes.
Potential changes to self-care management practices of people with type II diabetes could lead to a reduced utilization of the heath care system resulting in a positive economic impact.
|
baseline and 12 months
|
|
Changes in Diabetes Knowledge
Tidsramme: baseline, 3, 6, 9, 12 months
|
Changes in diabetes knowledge from baseline to 3, 6, 9, and 12 months will be measured using a 23 item multiple choice questionnaire devolopped by Fitzgerald et al 1998.
|
baseline, 3, 6, 9, 12 months
|
|
Changes in Diabetes self-care activities
Tidsramme: Baseline, 3, 6, 9 and 12 months
|
Changes in diabetes self-care activities from base line to 3, 6, 9, and 12 months will be measured the diabetes self-care activities tool evaluated by Toobert at al (2000).
|
Baseline, 3, 6, 9 and 12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Angela M Downey, PhD, CMA, FCMA, University of Lethbridge
- Ledende efterforsker: Helen Kelley, PhD, University of Lethbridge
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2007
Primær færdiggørelse (Faktiske)
1. december 2008
Studieafslutning (Faktiske)
1. december 2009
Datoer for studieregistrering
Først indsendt
3. marts 2011
Først indsendt, der opfyldte QC-kriterier
8. maj 2012
Først opslået (Skøn)
10. maj 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
10. maj 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. maj 2012
Sidst verificeret
1. maj 2012
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LAWSON-686
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 2
-
Instituto Nacional de Ciencias Medicas y Nutricion...Aktiv, ikke rekrutterende
-
Endogenex, Inc.Ikke rekrutterer endnuDiabetes mellitus, type 2 | Diabetes | Type 2 diabetes | Type 2 diabetes mellitus (T2DM) | Type 2 Diabetes
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi... og andre samarbejdspartnereIkke rekrutterer endnuType 2 diabetes | Diabetes mellitus type 2Tyrkiet (Türkiye)
-
Endogenex, Inc.Ikke rekrutterer endnuDiabetes mellitus, type 2 | Diabetes | Type 2 diabetes mellitus | Type 2 diabetes | Type 2 diabetes
-
El Katib HospitalIkke rekrutterer endnuType 2 diabetes mellitus (T2DM)
-
He Eye HospitalIkke rekrutterer endnu
-
Diabetes Solutions InternationalDexCom, Inc.; Tidepool; MAVEN ProjectRekrutteringType 2 diabetes mellitus (T2DM)Forenede Stater
-
Global Institute of Stem Cell Therapy and ResearchIkke rekrutterer endnu
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
Kliniske forsøg med eHealth education
-
State University of New York at BuffaloUniversity of OregonAktiv, ikke rekrutterendeAlkohol misbrugForenede Stater
-
Zagazig UniversityAfsluttetKræft | Kræft (tyktarmskræft, brystkræft, lymfom, kronisk lymfom leukæmi, multipelt myelom)Egypten
-
Royal College of Surgeons, IrelandAktiv, ikke rekrutterendeHoved- og halskræft (H&N)Irland
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentRekrutteringMetabolisk syndrom | e-sundhed | Livsstil | Svær psykisk lidelse | Somatisk screeningHolland
-
Aarhus University HospitalRekrutteringVedvarende fysiske symptomerDanmark
-
National Taiwan University HospitalRekruttering
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AfsluttetStillesiddende livsstilForenede Stater
-
Tufts Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD)Afsluttet
-
University of MiamiNational Institute on Drug Abuse (NIDA)AfsluttetStofbrug | Seksuel risikoadfærd | FamiliefunktionForenede Stater